ClinicalTrials.gg
Status unknownNCT04081922Updated May 5, 2022

Postoperative Analgesia With Erector Spinae Plane Block After Pectus Excavatum Repair in Children

An interventional study of Erector spinae plane block in Pectus Excavatum, sponsored by Seoul National University Hospital. Status unknown at 1 site in Korea, Republic of. Open to participants aged 3 Years to 7 Years. Per ClinicalTrials.gov, last updated 2022-05-05.

Sponsored by Seoul National University Hospital · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2022), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
3 Years to 7 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy of erector spinae plane (ESP) block in children after pectus excavatum repair (nuss procedure).

02

Conditions studied

  • Pectus Excavatum

Browse trials for

03

In context

Funnel Chest

79 studies on the registry are indexed under Funnel Chest; 10 are open to participants now.

This study's planned enrollment of 30 is below the median of 40 across 46 interventional studies indexed under Funnel Chest.

Browse Funnel Chest studies →

Lead sponsor

Seoul National University Hospital is the lead sponsor of 1,900 studies on the registry; 274 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 7 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 30 children aged between 3 and 7 years who undergo Nuss bar insertion due to Pectus excavatum

Exclusion criteria

Exclusion Criteria:

  • Allergy to opioid
  • Allergy to local anesthetics
  • Disease in heart, lung, kidney, and liver
  • Coagulation disorder
  • Disease in central and peripheral nervous system
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Regional analgesia using erector spinae plane block

    After pectus excavatum is done, intravenous patient controlled analgesia device with fentanyl is connected. Then, regional analgesia is performed for additional analgesia; ultrasound guided erector spinae plane block is performed using 0.25% ropivacaine (total 1 ml/kg) bilaterally. Plasma concentration of ropivacaine at baseline, and 5, 10, 20, 30, 60, 120 minutes after ropivacaine injection will be measured.

    Procedure: Erector spinae plane block

  • No intervention
    Control

    After pectus excavatum is done, intravenous patient controlled analgesia device with fentanyl is connected. No regional block is performed.

Interventions

  • ProcedureErector spinae plane block

    Using ultrasound, place the needle in the erector spinae fascia plane at T7-8 level. Then, 0.25% ropivacaine 0.5 ml is injected to confirm the needle location. After checking the location, 0.25% ropivacaine 0.5 ml/kg is administered. This procedure is repeated at contralateral side.

06

What researchers measure

Primary outcomes

  1. Pain score

    The Face, Legs, Activity, Cry, Consolability (FLACC) scale is used. FLACC scale is a measurement used to assess pain for children between the ages of 2 months and 7 years or individuals that are unable to communicate their pain. The scale is scored in a range of 0-10 with 0 representing no pain. The scale has five criteria, which are each assigned a score of 0, 1 or 2.

    Time frame: 1 hour after surgery

Secondary outcomes

  1. Fentanyl dosage (mcg/kg)

    Total dosage of fentanyl used postoperatively via patient controlled analgesia (mcg/kg)

    Time frame: until hospital discharge (postoperative day 3)

  2. Dose of rescue analgesics (mg/kg)

    If additional analgesics are required due to uncontrolled pain, intravnous acetaminophen and ketocin can be administered.

    Time frame: until hospital discharge (postoperative day 3

  3. Plasma concentration of ropivacaine

    Plasma concentration of ropivacaine after injection

    Time frame: 5, 10, 20, 30, 60, 120 minutes after injection

07

Study locations

1 of 1 sites recruiting
  • Seoul national university hospital
    Seoul, 03080, Korea, Republic of
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2020 (actual). Primary completion is estimated for Sep 2023, 43 months after the start.

Of 31 interventional studies with no phase under Funnel Chest, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 68. This study's planned 43 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2019
First posted
Sep 9, 2019
StartActual
Feb 10, 2020
Primary completionEst.
Sep 30, 2023
CompletionEst.
Dec 30, 2023
Last update
May 5, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04081922
Responsible party
Jin-Tae Kim (Professor, Seoul National University Hospital) — Principal investigator
First posted
Sep 9, 2019
Start date
Feb 10, 2020
Primary completion
Sep 30, 2023 (estimated)
Completion
Dec 30, 2023 (estimated)
Last update
May 5, 2022

Study contacts

Jin-Tae Kim, MD, PhD
Contact
jintae73@gmail.com
82-2-2072-3661
Jin-Tae Kim, MD, PhD
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion